However, PD-L1 expression was not a significant biomarker for response to anti-PD-1 in HCC as evidenced by the findings from ICB trials CheckMate 040 and KEYNOTE-224 (20, 91). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.